CanadiEM - By Andrew Shih - February 27, 2018
"Main Messages
- When managing DOAC-associated bleeding, consider the interventions that you would perform if the patient was not on a DOAC. Tranexamic acid has an excellent safety profile based on RCTs. Definitive procedural intervention remains the cornerstone of therapy.
- Specific reversal agents should be used whenever possible. PCCs and FEIBA are options in factor Xa inhibitor associated bleeding in the absence of a specific reversal agent, where thrombosis risk is low but should be discussed during consent.
- Plasma and platelet transfusion should only occur when indicated as if the patient was not on a DOAC."